
Take Q4 FY19 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- Company achieved a revenue of Rs. 2,039 Cr in FY2019, a 28.5% YoY growth in rupee terms and 19% in dollar terms, indicating strong growth momentum (Page 3).
- Order book for Life Sciences as of March 2019 stood at $245.12 million, up 36.6% YoY, reflecting robust sales pipeline (Page 4).
- Company expects continued strong growth aided by expansion in North America through recent acquisitions, enhancing full-service CRO capabilities (Page 8).
- Growth driven by differentiated technology platforms like OneClinical, expanded predictive modeling, workflow enablement, and expanded services across therapeutic areas (Pages 7-8).
- Expects to maintain EBITDA margins with some improvement from offshore delivery and operational efficiencies (Pages 14-15).
- Anticipates steady-state unbilled receivables around 15 days; working capital cycle expected to improve from ~120-130 days to about 90 days over two years (Page 17).
- Growth supported by continuing investments in IP, technology, and sales enablement assets (Pages 7, 15).
See what Take management said on margin guidance — free account, 30 seconds.
Fundraise plans
- TAKE Solutions currently has credit lines available to support growth for the next several quarters.
- They have maintained options to raise credit but have not specified any immediate new fundraises.
- The acquisition of $52 million for DataCeutics and KAI Research was funded out of internal accruals and previous capital infusion.
- The company currently holds a limited war chest of cash but has access to credit lines if needed.
- No explicit mention of plans for fresh equity fundraising or additional debt issuance was made for the near term.
- The focus appears to be on utilizing existing resources and credit facilities to support ongoing business and acquisitions.
See what Take management said on order book — free account, 30 seconds.
Capex plans
Yes- Internal capex requirements for FY2020 and FY2021 are generally manageable; the company feels fairly okay with current plans.
- Several work-in-progress intellectual properties (IPs) are at an interesting stage, expected to be capitalized and go to market soon.
- DataCeutics (DC) may not require much capex.
- KAI Research (KAI) is expected to require some investment; originally planned in the budget.
- Investment in KAI capex is anticipated to begin in one to two quarters from the discussion date (May 2019), not immediately.
- Overall, FY2020 capex is expected to be between Rs.120 Crores to Rs.150 Crores or possibly less.
Track Take — get its next earnings analysis in your feed
How does Take rank vs peers in Healthcare Services?
Pro featureHow does Take rank in Healthcare Services?
Compare Take against every Healthcare Services company (Q4 FY19) on revenue, margins and earnings-call signals.
Continue your research
What Take's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.